PRAX Latest Press Releases

-- December 4, 2025 --

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies Globe Newswire 4:10 PM

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor Globe Newswire 4:01 PM

-- December 3, 2025 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 24, 2025 --

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 4:01 PM

-- November 20, 2025 --

Praxis Precision Medicines to Participate in Upcoming Fireside Chat Globe Newswire 4:01 PM

-- November 5, 2025 --

Praxis Precision Medicines to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- November 4, 2025 --

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback Globe Newswire 8:00 AM

-- October 16, 2025 --

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering Globe Newswire 11:45 PM

Praxis Precision Medicines, Inc. Announces Proposed Public Offering Globe Newswire 4:01 PM

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor Globe Newswire 7:00 AM

-- October 2, 2025 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 29, 2025 --

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update Business Wire 7:00 AM

-- September 15, 2025 --

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:42 PM

-- September 13, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- September 8, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 3:30 PM

-- September 4, 2025 --

Praxis Precision Medicines to Participate in September Investor Conferences Globe Newswire 4:01 PM

Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm Globe Newswire 7:54 AM

-- September 3, 2025 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- August 29, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX Globe Newswire 10:05 AM

Praxis Precision Medicines to Participate in Upcoming Fireside Chat Globe Newswire 8:00 AM

-- August 27, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- August 25, 2025 --

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline Globe Newswire 4:01 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX Globe Newswire 12:13 PM

-- August 23, 2025 --

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:32 AM

-- August 22, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- August 21, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX Globe Newswire 2:16 PM

-- August 16, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- August 13, 2025 --

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm Business Wire 5:32 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX Globe Newswire 10:59 AM

-- August 11, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 10:00 AM

-- August 9, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX Globe Newswire 11:33 AM

-- August 6, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX PRNewswire 6:40 PM

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 5, 2025 --

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm Globe Newswire 5:50 PM

-- August 4, 2025 --

Praxis Precision Medicines to Participate in Upcoming Fireside Chat Globe Newswire 8:24 PM

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results Globe Newswire 8:30 AM

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine Globe Newswire 8:00 AM

-- July 29, 2025 --

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results Globe Newswire 8:00 AM

-- July 17, 2025 --

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies Globe Newswire 8:00 AM